ALNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alnylam Pharmaceuticals Inc (ALNY) is not a strong buy at the moment for a beginner, long-term investor. The technical indicators suggest a bearish trend, and there are no strong trading signals from Intellectia Proprietary Trading Signals. While analysts are optimistic about the long-term potential and the company has positive news regarding its pipeline and R&D investments, the current price trend and lack of significant catalysts make this a hold rather than a buy.
The technical indicators for ALNY are bearish. The MACD is negatively expanding, RSI is neutral at 30.873, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 276.666), with resistance levels far above the current price.
Analysts see long-term potential in the company's Amvuttra product and its expanded pipeline. The company is increasing R&D investments and aims to grow its clinical programs significantly by 2030.
The stock has faced pressure from competitor concerns, and recent price movements have been bearish. There is no recent congress trading data or significant insider/hedge fund activity to indicate strong confidence.
No financial data is available for the latest quarter, making it difficult to assess the company's recent growth trends.
Analysts have a generally positive outlook, with Citi initiating a Buy rating and a $380 price target, citing the 28% YTD pullback as an attractive entry point. Other analysts have maintained high price targets, but some have lowered them slightly due to seasonal weaknesses and competitive pressures.
